The PREPAReS Study: Pathogen Reduction Evaluation & Predictive Analytical Rating Score.

Official Title

Clinical effectiveness of standard versus pathogen-reduced buffy coat-derived platelet concentrates in plasma in hemato oncological patients.


The study is a prospective, randomized multicenter trial for the evaluation of platelet products in hemato oncological patients with thrombocytopenia or expected to become thrombocytopenic caused by myelosuppressive therapy or malignancy-related myelosuppression. In this trial patients will be randomized to receive one of two platelet products during a transfusion episode with a maximum of 6 weeks. Because the Mirasol-treated platelet products show a color difference not allowing an appropriate placebo, the study will be single-blinded for investigators evaluating the bleeding score.
Products will be stored up to 7 days. The primary endpoint is restricted to 5 days storage as this implies the most relevant information. Secondary endpoint evaluation requires that the patient continues treatment in the assigned study arm.Arm A: Plasma stored platelet concentrates (Plasma-PCs);Arm B: Pathogen reduced plasma-stored platelet concentrates (PR-plasma-PCs).

Trial Description

Primary Outcome:

  • WHO grade ≥ 2 bleeding complications of PCs
Secondary Outcome:
  • Using PCs, stored for 1-7 days:
  • 1. The 1 and 24 hour CI;
  • 2. The 1 and 24 hour CCI;
  • 3. (1+24 hour CCI)/2;
  • 4. Adverse transfusion reactions;
  • 5. Total transfusion requirement of red cells and platelets;
  • 6. Platelet transfusion interval;
  • 7. Rate of HLA allo-immunization;
  • 8. In vitro quality markers related with the 1-hour or 24-hour CCI;
  • 9. Clinical factors interacting on primary endpoint, including in vivo variables of immunological responses and of hemostasis in the recipients after transfusion as compared prior to transfusion.

Interested in this trial?

Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.


Canadian Cancer Society

These resources are provided in partnership with the Canadian Cancer Society